Proactively manage new and pipeline therapies
Traditional forecasting methods use historical claims data, which doesn’t help you predict the impact of new therapies. HTP bridges this gap by using clinical expertise and robust data insights to develop actuarial forecasts. These forecasts help project trends and identify therapies for cost and utilization management, covering both commercial and Medicare lines of business for medical and pharmacy drugs.
Customize your forecasts based on demographics, cost and adoption
HTP’s customization tool allows users to tailor modeling assumptions to accurately reflect their membership. Customize based on demographic splits, utilization, adoption, and direct and offsetting costs. You can also customize your view, such as breaking out PMPM impacts by therapeutic category or by IP/OP/PHY/Rx impacts.
Q: Does HTP include all pipeline drugs?
A: HTP includes brand drugs that are expected to impact medical and/or pharmacy claims costs, such as:
- First-in-class, new mechanism of action
- High expected cost
- High expected utilization
- Unmet need: Therapies for diseases with few, if any, effective treatments currently on the market
- Therapies that lower overall claims cost: e.g. a new brand oral drug that replaces a medical infusion
HTP does not include generics, biosimilars, or medical devices.
Q: What data is used to develop HTP forecasts?
A: HTP forecasts are developed using Optum’s proprietary data and deep experience.
Q: How often is HTP updated?
A: HTP is updated quarterly on the 3rd Monday of February, May, August, and November. Each quarter, forecasts of new drugs are added to the HTP website, and the forecasts of drugs currently in HTP are revised with the latest available information.
Marketplace updates
Subscribe to The Spark
We're adding new products and services to rapidly expand our marketplace and the potential is huge. Be an early adopter and stay ahead of the trend with our bi-weekly e-updates.
Your account is almost complete! To quickly access your account,